Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) stated on Wednesday that it plans to launch the clinical trials of its cannabinoid Sol-gel to reduce the possibility of contracting coronavirus infections.
In conjunction with the COVID-19 Sol-Gel clinical programme, the company has retained Veristat, a global clinical research organization (CRO) located in Massachusetts, USA, to assist with planning the clinical trial process and writing the required protocols.
Pursuant to the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical programme and required protocol.
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
D3 Bio completes USD108m Series B financing round
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
Champions Oncology expands bioanalytical services with new technology and leadership
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
Poolbeg Pharma trial to feature in major CRS research programme
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Proteome Sciences wins third US biopharma contract for new clinical assay
Lundbeck reports results from long-term follow-up of epilepsy patients treated with bexicaserin
CARsgen Therapeutics presents CT0596 study data at 2005 ASH Annual Meeting
AsymBio starts commercial production at Shanghai Fengxian Manufacturing Base
Innovent Biologics and Takeda sign global strategic partnership